<!DOCTYPE html>
<html manifest="manifest.manifest">
<head>
	<meta http-equiv=Content-Type content="text/html; charset=utf-8">
	<title>MRCG Clinical Guidelines</title>
	<meta name="viewport" content="width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=2.0, user-scalable=1">
	<meta name=Generator content="Microsoft Word 14 (filtered)">
	<link rel="manifest" href="/manifest.json">	
<link rel="stylesheet" href="jquery.mobile-1.4.5.min.css" />
	<link rel="stylesheet" href="mystyle.css" />
	<script src="jquery-1.11.1.min.js"></script>
	<script src="jquery.mobile-1.4.5.min.js"></script>
	<script type="text/javascript" src="cordova.js"></script>
	<script>
	    		$(function(){
			$("[data-role='header'], [data-role='footer']").toolbar();
		});
  	  $(document).one('pagebeforecreate', function () {
	        $('input[data-type="search"]').val("");
	    	        $.get("panel.html", function (data2) {
            $.mobile.pageContainer.prepend(data2);
              $("[data-role=panel]").panel().enhanceWithin();
        }, "html");
	           $.get("header.html", function (data) {
      $.mobile.pageContainer.prepend(data);
      $("[data-role='header']").toolbar().enhanceWithin();
    }, "html");
    $.get("footer.html", function (data) {
      $.mobile.pageContainer.append(data);
      $("[data-role='footer']").toolbar().enhanceWithin();
    }, "html");
        $('.WordSection1').wrap('<div role="main" class="ui-content">');
        $('table').wrap('<div class="tableCont"></div>');
        $('img').wrap('<div class="tableCont"></div>');
        $.mobile.pageContainer.enhanceWithin();
	  });
	        $(document).bind( "pagechange", function( ) {
        $('table').wrap('<div class="tableCont"></div>');
        $('img').wrap('<div class="tableCont"></div>');
        $('.tableCont').enhanceWithin();
      } );
			// When the user scrolls down 20px from the top of the document, show the button
		window.onscroll = function() {scrollFunction()};
		function scrollFunction() {
		  if (document.body.scrollTop > 20 || document.documentElement.scrollTop > 20) {
			document.getElementById("myBtn").style.display = "block";
		  } else {
			document.getElementById("myBtn").style.display = "none";
		  }
		}
		// When the user clicks on the button, scroll to the top of the document
		function topFunction() {
		  document.body.scrollTop = 0; // For Safari
		  document.documentElement.scrollTop = 0; // For Chrome, Firefox, IE and Opera
		}</script>      



	


  

</head>
<body lang=EN-GB link=blue vlink=purple>
	<div data-role="header" data-tap-toggle="false" data-id="persistent-header" data-position="fixed" data-theme="a">
		<h2 style="font-size:0.75em;">MRCG<br>Clinical Guidelines<br></h2>
		<a data-rel="back" class="ui-btn ui-corner-all ui-btn-inline ui-mini header-button-left ui-btn-icon-left ui-icon-carat-l">Back</a>
<a href="#leftpanel1" class="ui-btn ui-shadow ui-corner-all ui-btn-inline ui-mini header-button-left ui-icon-info ui-btn-icon-notext">About this app</a>
		<a href="#popupNested"  class="ui-btn ui-corner-all ui-shadow ui-btn-inline ui-icon-bars ui-btn-icon-right ui-btn-b header-button-right" data-transition="pop">Choose a guideline...</a>
		prolapse_MeG-CLS-015.html">Rectal prolapse</a></li>
			<li><a href="Rheumatic_heart_disease_MeG-CLS-065.html">Rheumatic heart disease</a></li>
			<li><a href="Scabies_MeG-CLS-066.html">Scabies</a></li>
			<li><a href="Sepsis_in_adults_MeG-CLS-043.html">Sepsis in adults</a></li>
			<li><a href="Sinusitis_MeG-CLS-062.html">Sinusitis</a></li>
			<li><a href="Stevens-Johnsons_syndrome_MeG-CLS-067.html">Stevens-Johnsons syndrome</a></li>
			<li><a href="STI_MeG-CLS-038.html">Sexually Transmitted Infections</a></li>
			<li><a href="Stroke_MeG-CLS-020.html">Stroke</a></li>
			<li><a href="TB_MeG-CLS-044.html">TB</a></li>
			<li><a href="Tonsillitis_and_pharyngitis_MeG-CLS-024.html">Tonsillitis and pharyngitis</a></li>
			<li><a href="Trauma_MeG-CLS-068.html">Trauma</a></li>
			<li><a href="Upper_respiratory_tract_infections_MeG-CLS-018.html">Upper respiratory tract infections</a></li>
			<li><a href="UTI_MeG-CLS-019.html">Urinary tract infections</a></li>
</ul>
		</div>
		</div>
	  </div>
	 
    </div><!-- /header -->
<div data-role="page">
	<div role="main" class="ui-content">
<div class=WordSection1>
<h1><span lang=EN-US>Rheumatic heart disease</span></h1>
<h2><i><span lang=EN-US>Executive summary</span></i></h2>
<h2><span lang=EN-US>Introduction</span></h2>
<p class=MsoNormal><span lang=EN-US>Rheumatic heart disease (RHD) is a serious
complication of rheumatic fever. It refers to the chronic heart valve damage
that can develop years after single or repeated episodes of acute rheumatic
fever (ARF). Acute rheumatic fever is an inflammatory autoimmune disease which
occurs following inadequately treated infection with Group A Streptococcus
(GAS). Repeated episodes of ARF can lead to inflammation of the heart either on
the surface of the heart (pericarditis), within the heart (endocarditis)
leading to accumulative damage to one or more of the four heart valves
(endocarditis) or involving the heart muscle itself (myocarditis). Untreated
RHD can lead to heart failure, stroke, arrhythmia and complications in
pregnancy.</span></p>
<p class=MsoNormal><span lang=EN-US>RHD is a disease of poverty, associated
with overcrowding and poor living conditions, as well as lack of access to
health care and services.</span></p>
<p class=MsoNormal><span lang=EN-US>Group A streptococcal infection, acute
rheumatic fever and rheumatic heart disease are preventable with improved
housing and living conditions, and early antibiotic treatment.</span></p>
<h2><span lang=EN-US>Target users</span></h2>
<p class=MsoListParagraphCxSpFirst style='margin-left:39.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Doctors </span></p>
<p class=MsoListParagraphCxSpLast style='margin-left:39.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Nurses</span></p>
<h2><span lang=EN-US>Target area of use </span></h2>
<p class=MsoListParagraphCxSpFirst style='margin-left:39.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Outpatient department</span></p>
<p class=MsoListParagraphCxSpLast style='margin-left:39.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Ward</span></p>
<h2><span lang=EN-US>Key areas of focus / New additions / Changes </span></h2>
<p class=MsoNormal><span lang=EN-US>This guidelines describes the initial
diagnosis and management of rheumatic heart disease. Advanced rheumatic heart
disease requires surgical treatment which is delivered through a partnership
with the UK charity Chain of Hope. Management of these children is shared with
overseas paediatric cardiologists who will advise on more complex problems. </span></p>
<h2><span lang=EN-US>Limitations</span></h2>
<p class=MsoNormal><span lang=EN-US>Access to surgery is limited and many
children must be managed medically.</span></p>
<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>
<span lang=EN-US style='font-size:11.0pt;font-family:"Arial","sans-serif"'><br
clear=all style='page-break-before:always'>
</span>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
lang=EN-US style='font-size:12.0pt'>&nbsp;</span></b></p>
<h2><span lang=EN-US>Presenting symptoms and signs</span></h2>
<p class=MsoNormal><span lang=EN-US>The most common forms of RHD include mitral
valve disease (mitral stenosis, mitral regurgitation), aortic valve disease
(aortic stenosis, aortic regurgitation) and tricuspid regurgitation. Atrial
fibrillation is often associated with mitral stenosis.</span></p>
<p class=MsoNormal><span lang=EN-US>Clinical features of RHD vary depending on
which heart valves are affected and how severely. Early in the onset of disease,
cases may be asymptomatic for many years. As valvular disease progresses, cases
will have symptoms of some degree of heart failure, ranging from mild to severe
exertional dyspnoea, fatigue, peripheral oedema and palpitations. The severity
of RHD increases with repeated episodes of ARF.</span></p>
<p class=MsoNormal>Complications of RHD include heart failure, stroke,
arrhythmias, infective endocarditis and complications during pregnancy. Heart
failure is the major cause of disability and death from RHD. Infective endocarditis
is more likely to occur when there is damage to the heart valves and is a
serious illness requiring hospitalisation and intravenous antibiotics, which is
also associated with a significant mortality and morbidity burden.</p>
<p class=MsoNormal><span lang=EN-US>Other symptoms due to rheumatic heart
disease are:</span></p>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Chest pain.</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Heart palpitations.</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Shortness of breath especially with physical
exertion.</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Swollen ankles, legs, wrists, and stomach.</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Excessive fatigue.</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Thumping sensation in chest.</span></p>
<h2><span lang=EN-US>Examination findings</span></h2>
<p class=MsoNormal><span lang=EN-US>These vary with the severity of valve
calcification, the severity of stenosis, and left ventricular (LV) function. </span></p>
<p class=MsoNormal><span lang=EN-US>With mild disease, the apex beat is brisk
and hyper dynamic. The S<sub>1</sub> is usually soft, and a widely split S<sub>2</sub>
is common. A diastolic rumble and S<sub>3</sub> may be present even if there is
no LV dysfunction.</span></p>
<p class=MsoNormal><span lang=EN-US>With severe mitral regurgitation (MR), the
apex may be enlarged and displaced laterally. The systolic murmur of MR varies
according to its cause. It is usually heard best at the apex in the left
lateral decubitus position. With severe degenerative MR, the murmur is
holosystolic, radiating into the axilla. Early systolic murmurs are typical of
acute MR. Late systolic murmurs are typical of mitral valve prolapse or
papillary muscle dysfunction. </span></p>
<p class=MsoNormal><span lang=EN-US>Signs of pulmonary hypertension, such as a
loud P<sub>2</sub>, represent advanced</span><span lang=EN-US> </span><span
lang=EN-US>disease.</span></p>
<h2><span lang=EN-US>Differential diagnosis</span></h2>
<p class=MsoNormal><span lang=EN-US>The main alternative diagnosis in children
is infectious endocarditis or congenital heart disease. In adults, valvular
heart disease might be due to degenerative changes.</span></p>
<span lang=EN-US style='font-size:11.0pt;font-family:"Arial","sans-serif"'><br
clear=all style='page-break-before:always'>
</span>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
lang=EN-US style='font-size:12.0pt'>&nbsp;</span></b></p>
<h2><span lang=EN-US>Investigations</span></h2>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-US>CXR </span></b></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Heart failure: enlarged heart, congested
pulmonary vasculature. If more severe: enlarged right atrium and right
ventricle.</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Chronic MR: cardiomegaly (LV and LA
enlargement). </span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Acute MR or progressive LV failure: Kerley B
lines and interstitial oedema.</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Pulmonary hypertension: right-sided chamber
enlargement.</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Severe mitral stenosis: left atrial enlargement.</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-US>ECG</span></b><span lang=EN-US> – Looking for
LV hypertrophy, LA enlargement, conduction abnormality (left and right bundle
branch block), altered axis, atrial fibrillation.</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-US>ECHO</span></b><span lang=EN-US> – Essential
to confirm the diagnosis and grade the severity of disease. </span></p>
<p class=MsoNormal><span lang=EN-US>Other investigations are not available in
the Gambia.</span></p>
<h2><span lang=EN-US>Management </span></h2>
<p class=MsoNormal><span lang=EN-US>There are 2 goals in treating RHD:</span></p>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US>Prevention of further damage to the heart valves.</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US>Treatment of heart failure.</span></p>
<h3><span lang=EN-US>Prevention of further damage to the valves</span></h3>
<p class=MsoNormal><span lang=EN-US>Primary prevention involves the use of
antibiotics to treat GAS throat infections.</span></p>
<p class=MsoNormal><span lang=EN-US>Secondary prevention of ARF: once a person
has had ARF, it is important to prevent future episodes, this is best provided
by monthly IM injections of Benzathine penicillin at a dose of 1.2 MU. This is
increased to 3 weekly if the patient is at especially high risk. It should be
continued until 10 years after the last episode of ARF or the age of 21 years.
This treatment reduces the number of ARF episodes and should be offered to all
patients with rheumatic carditis. For persons with established rheumatic heart
disease, secondary prevention with continuous antibiotics should be continued
for longer periods – even for life. It is also continued even after valve
surgery. </span></p>
<p class=MsoNormal><span lang=EN-US>Penicillin V has been used in place of Benzathine
penicillin. Patients prefer it, but there is concern that it is less effective
because it depends on them taking medication every day. There is no evidence to
support its use.</span></p>
<h3><span lang=EN-US>Treatment of heart failure</span></h3>
<p class=MsoNormal><u><span lang=EN-US>Medical treatment</span></u></p>
<p class=MsoNormal><b><span lang=EN-US>ACE inhibitors</span></b><span
lang=EN-US> block the formation of angiotensin II, this medication lowers blood
pressure and reduces sodium retention in people who have heart failure. They
are relatively contraindicated in patients with mitral or aortic stenosis. </span></p>
<p class=MsoNormal><span lang=EN-US>Use enalapril 100 micrograms/kg OD
initially. The dose can be increased up to 1 mg/kg OD. The maximum dose is 10
mg OD. Ramipril or captopril can be substituted according to availability.</span></p>
<p class=MsoNormal><b><span lang=EN-US>Beta blockers</span></b><span
lang=EN-US> block the effect of adrenaline on the heart to reduce excess stress
on the failing heart. These medications are most commonly used for dilated
cardiomyopathy.</span></p>
<p class=MsoNormal><span lang=EN-US>Use bisoprolol 1.25 mg OD in older
children. Use in younger children only on the advice of a cardiologist.</span></p>
<p class=MsoNormal><b><span lang=EN-US>Diuretics</span></b><span lang=EN-US> stimulate
the body to lose water by acting on the kidneys. This effect decreases fluid
retention and edema and provides symptomatic relief to the patient.</span></p>
<p class=MsoNormal><span lang=EN-US>Start with furosemide 0.5 mg/kg OD. The
dose can be increased as high as 12 mg/kg, but it is unusual to need doses
higher that 2 mg/kg OD.</span></p>
<p class=MsoNormal><span lang=EN-US>Add spironolactone 1 mg/kg OD. The dose can
be increased up to 9 mg/kg OD, but usually lower doses are needed in heart
failure.</span></p>
<p class=MsoNormal><u><span lang=EN-US>Surgical treatment</span></u></p>
<p class=MsoNormal><span lang=EN-US>Patients with significant heart failure
should be considered for valve repair or replacement surgery. In an ideal
world, even asymptomatic patients should be considered for this in order to
prevent significant heart damage. </span></p>
<p class=MsoNormal><span lang=EN-US>Patients are often very young when operated
and, therefore, are given mechanical valves if they need replacement surgery,
as they last longer. However, they then require warfarin treatment. Girls
offered mechanical valves should be counselled about the risks of being
pregnant on warfarin treatment and about the option of using low-molecular
weight heparin through the pregnancy. The target INR is usually 2.5-3.5.</span></p>
<h2><span lang=EN-US>Key Issues for Nursing care</span></h2>
<h2><span lang=EN-US style='font-size:11.0pt;font-weight:normal'>Make sure
patients and their caregivers understand why they have been given penicillin
prophylaxis and how important it is to prevent further episodes of ARF.</span></h2>
<h2><span lang=EN-US>References</span></h2>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Queensland Health
Guidelines</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maganti, K.,
Rigolin,V.H., Sarano, M.E.,MD, and Bonow, R.O. Valvular Heart Disease:
Diagnosis and Management. Mayo Clin Proc. 2010. 85(5): 483–500.</span></p>
<div class="tableCont">
  <table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Written by:</span></b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Name: Baderinwa Abatan</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Date: 13 March 2019</span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Reviewed by:</span></b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Name: Karen Forrest</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Date: 07 May 2019</span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Version:</span></b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Change history:</span></b></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Review due date:</span></b></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>1.0</span></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>New document</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>31 May 2021</span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Review Comments (<i>if applicable)</i></span></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>&nbsp;</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>&nbsp;</span></b></p>
  </td>
 </tr>
</table>
</div>
<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
</div>
</div><!-- /content -->

</div>

</body>
</html>
